

FORM PTO-1449 <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>  <small>(37 CFR 1.98(d))</small>	ATTY DOCKET NO.: 270.PFUS	SERIAL NO.: 10/540794
	APPLICANT: Dahl et al	
	FILING DATE: 3/20/2006	GROUP ART UNIT: 1616
	EXAMINER NAME:	

DEC 08 2006

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initial	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T

NON PATENT LITERATURE DOCUMENTS		
Examiner detail	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
/A.P./		GILEAD SCIENCES, INC., "Gilead Sciences to Acquire Triangle Pharmaceuticals for \$464 Million" Gilead to Launch Coviracil in 2003 Will Develop Co-Formulation of Viread and Coviracil", Press Release, 2002

**EXAMINER** /Alton Pryor/ **DATE CONSIDERED** 05/14/2007  
**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

<b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(37 CFR 1.98(b))</small>		ATTY DOCKET NO.: 270.PFUS    SERIAL NO.: 10/540,794	
		APPLICANT: Dahl et al	
		FILING DATE: 3/20/2006	GROUP ART UNIT: 1616
		EXAMINER NAME:	
Sheet 1 of 1			

*JAN 22 2007*

PATENT & TRADEMARK OFFICE

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner initial	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
					T

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column-issue number(s), publisher, city and/or country where published.	T
/A.P./		DE CLERCQ E., "Highlights in the Development of New Antiviral Agents", 2(2): 163-175, MINI REV MED CHEM, 2002	
/A.P./		DE CLERCQ E., "New Developments in anti-HIV chemotherapy", 56(1-2): 3-12, Farmaco, 2001	
/A.P./		DE CLERCQ E., "New Development in Anti-HIV Chemotherapy", 8(13):1543-72, CURRENT MEDICINAL CHEMISTRY, 2001	
/A.P./		ISHIDA K, ASAO T., "Self-association and Unique DNA Binding Properties of the Anti-Cancer Agent TAS-103, a Dual Inhibitor of Topoisomerases I and II", 1587(2-3):155-163, BIOCHEM BIOPHYS ACTA, 2002	
/A.P./		LIU ET AL., "Thymidylate Synthase as a Translational Regulator of Cellular Gene Expression.", 1587(2-3):174-182, BIOCHEM BIOPHYS ACTA, 2002	

EXAMINER	/Alton Pryor/	DATE CONSIDERED	05/14/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			